GSK and Pfizer sign joint venture, but will demerge after three years
20-12-2018
© GSK
Swiss pharmaceutical company Novartis can buy London-based GlaxoSmithKline’s (GSK) portfolio of cancer drugs after it agreed to meet certain conditions set by the US Federal Trade Commission (FTC), the agency has said.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FTC, Novartis, GSK, M&A, cancer, BRAF, MEK
